US3071509A - N-alkyl-nornicotine:nicotine antagonist - Google Patents

N-alkyl-nornicotine:nicotine antagonist Download PDF

Info

Publication number
US3071509A
US3071509A US9444661A US3071509A US 3071509 A US3071509 A US 3071509A US 9444661 A US9444661 A US 9444661A US 3071509 A US3071509 A US 3071509A
Authority
US
Grant status
Grant
Patent type
Prior art keywords
dosage
nicotine
alkyl
mgm
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
Inventor
Robert C O'neill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stauffer Chemical Co
Original Assignee
Stauffer Chemical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Grant date

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00

Description

United States Patent Ofifice Patented Jan. 1, 1963 3,071,509 N-Atkrt-Noarstcornsnuutcornsn ANrAooNisr No Drawing. Filed Mar. 9, 1961, Ser. No. 94,446 4 flaims. (Cl. 167-55) The present invention is concerned with certain novel pharmaceutical dosage forms. In particular, it is concerned with unitary dosage forms of certain compounds which I have found exert a physiological response antagonistic to that of nicotine.

The present application is a continuation in part of my copending application Serial Number 3,718, filed on January 21, 1960, noW Patent No. 2,981,641.

Many persons who smoke tobacco desire to break the smoking habit, or at least to diminish the amount of smoking. The reasons for such desire are many and varied, any may be based on advice from a physician or purely on economic considerations. in any case, it has been the experience of numerous smokers, and particularly of very heavy smokers, that it is very difficult to give up the tobacco habit. There are also many persons upon whom the nicotine absorbed from smoked tobacco exerts an undesired effect, for example, upon blood pressure or gastric secretion.

The present invention provides a help to the solution of the above problems. According to the present invention, the smoker orally ingests a unitary dosage form of a nicotine antagonist.

The nicotine antagonists useful in the present invention are compounds which are chemically related to nicotine itself, but they differ from nicotine in that the methyl group present on the nitrogen atom in the 5- membered ring of nicotine has been replaced by a lower alkyl group containing from 2 to 8 carbon atoms. The compounds are, chemically, N-alkyl nornicotines. As examples of suitable alkyl groups, there may be mentioned ethyl, propyl, isopropyl, hexyl, isobutyl, octyl, and, preferably, allyl, which is an unsaturated alkyl group.

The antagonist may be used in the form of thefree base, but it is preferred to use it in the form of an acid addition salt. The salt may be of any non-toxic acid, for example, citric acid, m-alic acid, acetic acid, hydrochloric acid, sulfuric acid, phosphoric acid, and the like.

When taken by the smoker, the nicotine antagonists of the present invention diminish the physiological responses elicited in the smoker by nicotine and the related alkaloids absorbed from the smoke.

On the average, about 3 to 4 mgm. of nicotine are absorbed from the puffed smoke of an average cigarette. The smoke of a 10 gram cigar may contain some to more than 40 mgm. of nicotine. (See Goodman and Gilman, The Pharmacological Basis of Therapeutics, 2nd Edition, 1956, p. 624.) The dosage of the antagonist should be of approximately the same order of magnitude as the amount of nicotine absorbed by the smoker. For the majority of smokers, the daily dosage will be from about 5 mgm. to about 250 mgrn. Particularly in the case of dosages toward the upper end of this range, the antagonist is preferably taken in split dosages, say three or four a day. Most desirably, the dosage is taken in the form of a sustained release capsule or tablet.

The unitary dosage forms of the present invention may be formulated in accordance with conventional practices well-known in the art. Any compatible inert excipient may be used. Examples include starch, milk sugar, calcium phosphate and the like. The preparation of sustained release dosage forms is also a well developed art, and such forms of the antagonist may be prepared in accordance With Well-known methods.

Example I Fifty mgm. of the citrate salt of N-alkyl nornicotine is mixed with 200 mgm. of starch, and the mixture is pressed into a tablet. One such tablet is taken at each of 3 meals daily by a smoker who averages forty cigarettes a day. The usual physiological responses due to smoking are diminished, and the craving for tobacco is decreased.

The foregoing example is given solely for the purposes of illustration and is not to be construed as limitation of the invention, many variations of which will occur to those skilled in the art Without departing from the spirit or scope thereof.

What is claimed is:

1. A unitary dosage form suitable for oral ingestion comprising from about 5 to about 250 mgm. of a compound selected from the group consisting of N-alkyl nornico-tine compounds containing from 2 to 8 carbon atoms in the alkyl group, and addition salts thereof with non-toxic acids, together with a carrier.

2. A sustained release unitary dosage form suitable for oral ingestion comprising from about 5 to about 250 mgm. of a compound selected from the group consisting of N-alkyl nornicotine compounds containing from 2. to 8 carbon atoms in the alkyl group, and addition salts thereof with non-toxic acids.

3. A unitary dosage form suitable for oral ingestion, comprising from about 5 to about 250 mgm. of the citrate of N-allyl nornicotine together with a carrier.

4. A sustained release unitary dosage form suitable for oral ingestion comprising from about 5 to about 250 mgm. of the citrate of N-allyl nornico-tine.

References Cited in the file of this patent UNITED STATES PATENTS 2,981,641 ONeill Apr. 25, 1961

Claims (1)

1. A UNITARY DOSAGE FORM SUITABLE FOR ORAL INGESTION COMPRISING FROM ABOUT 5 TO ABOUT 250 MGM. OF A COMPOUND SELECTED FROM THE GROUP CONSISTING OF N-ALKYL NORNICOTINE COMPOUNDS CONTAINING FROM 2 TO 8 CARBON ATOMS IN THE ALKYL GROUP, AND ADDITION SALTS THEREOF WITH NON-TOXIC ACIDS, TOGETHER WITH A CARRIER.
US3071509A 1961-03-09 1961-03-09 N-alkyl-nornicotine:nicotine antagonist Expired - Lifetime US3071509A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US3071509A US3071509A (en) 1961-03-09 1961-03-09 N-alkyl-nornicotine:nicotine antagonist

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3071509A US3071509A (en) 1961-03-09 1961-03-09 N-alkyl-nornicotine:nicotine antagonist

Publications (1)

Publication Number Publication Date
US3071509A true US3071509A (en) 1963-01-01

Family

ID=22245252

Family Applications (1)

Application Number Title Priority Date Filing Date
US3071509A Expired - Lifetime US3071509A (en) 1961-03-09 1961-03-09 N-alkyl-nornicotine:nicotine antagonist

Country Status (1)

Country Link
US (1) US3071509A (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4574151A (en) * 1982-08-20 1986-03-04 Peter Robin Broughton Lawrence Amine salts and products containing them
US4806356A (en) * 1983-06-29 1989-02-21 Shaw Alec S W Tobacco product
US5122366A (en) * 1989-01-21 1992-06-16 The Arab Pharmaceutical Company Antismoke mouth wash comprising silver nitrate and propylene glycol
US5316759A (en) * 1986-03-17 1994-05-31 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
US20080221085A1 (en) * 2004-07-15 2008-09-11 Universite Laval Nicotinic Receptor Agonists for the Treatment of Inflammatory Diseases
US20080233197A1 (en) * 2006-06-19 2008-09-25 Francis Joseph Matthews Pharmaceutical compositions
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US20100152221A1 (en) * 2007-12-17 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US20100266645A1 (en) * 2007-12-17 2010-10-21 Alfred Liang Pharmaceutical compositions
US20110014280A1 (en) * 2002-09-20 2011-01-20 Garth Boehm Sequestering subunit and related compositions and methods
US8557804B2 (en) 2002-03-25 2013-10-15 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2981641A (en) * 1960-01-21 1961-04-25 Stauffer Chemical Co Tobacco products

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2981641A (en) * 1960-01-21 1961-04-25 Stauffer Chemical Co Tobacco products

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4574151A (en) * 1982-08-20 1986-03-04 Peter Robin Broughton Lawrence Amine salts and products containing them
US4806356A (en) * 1983-06-29 1989-02-21 Shaw Alec S W Tobacco product
US5316759A (en) * 1986-03-17 1994-05-31 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
US5574052A (en) * 1986-03-17 1996-11-12 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
US5935975A (en) * 1986-03-17 1999-08-10 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
US5122366A (en) * 1989-01-21 1992-06-16 The Arab Pharmaceutical Company Antismoke mouth wash comprising silver nitrate and propylene glycol
US8557804B2 (en) 2002-03-25 2013-10-15 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
US8551983B2 (en) 2002-03-25 2013-10-08 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
US8685443B2 (en) 2002-09-20 2014-04-01 Alpharma Pharmaceuticals Llc Sequestering subunit and related compositions and methods
US20110014280A1 (en) * 2002-09-20 2011-01-20 Garth Boehm Sequestering subunit and related compositions and methods
US20110027455A1 (en) * 2002-09-20 2011-02-03 Garth Boehm Sequestering subunit and related compositions and methods
US8685444B2 (en) 2002-09-20 2014-04-01 Alpharma Pharmaceuticals Llc Sequestering subunit and related compositions and methods
US8039459B2 (en) 2004-07-15 2011-10-18 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
US20080221085A1 (en) * 2004-07-15 2008-09-11 Universite Laval Nicotinic Receptor Agonists for the Treatment of Inflammatory Diseases
US8877247B2 (en) 2006-06-19 2014-11-04 Alpharma Pharmaceuticals Llc Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist
US8846104B2 (en) 2006-06-19 2014-09-30 Alpharma Pharmaceuticals Llc Pharmaceutical compositions for the deterrence and/or prevention of abuse
US20100143483A1 (en) * 2006-06-19 2010-06-10 Alpharma Pharmaceuticals, Llc. Pharmaceutical compositions
US7682633B2 (en) 2006-06-19 2010-03-23 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US8158156B2 (en) 2006-06-19 2012-04-17 Alpharma Pharmaceuticals, Llc Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist
US7682634B2 (en) 2006-06-19 2010-03-23 Alpharma Pharmaceuticals, Llc Pharmaceutical compositions
US20090162450A1 (en) * 2006-06-19 2009-06-25 Alpharma Pharmaceuticals, Llc. Pharmaceutical composition
US20080233197A1 (en) * 2006-06-19 2008-09-25 Francis Joseph Matthews Pharmaceutical compositions
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US20100266645A1 (en) * 2007-12-17 2010-10-21 Alfred Liang Pharmaceutical compositions
US20100152221A1 (en) * 2007-12-17 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition

Similar Documents

Publication Publication Date Title
US3667478A (en) Filter cigarette incorporating vitamin a
Auerbach et al. Emphysema produced in dogs by cigarette smoking
Russell et al. Cigarette smoking: a dependence on high-nicotine boli
Bynum et al. Inhibition of pancreatic secretion in man by cigarette smoking
US20050034738A1 (en) Chewing tobacco substitute containing nicotine
US4256755A (en) Method of using N-substituted dihydro-2-oxazolamines as analgesics
US4690927A (en) Pharmaceutical compositions with analgesic properties and the preparation and use thereof
US3795739A (en) Treatment of parkinson disease
Loewe Studies on the pharmacology and acute toxicity of compounds with marihuana activity
US5783207A (en) Selectively removable nicotine-containing dosage form for use in the transmucosal delivery of nicotine
Johnson et al. Some cardiovascular effects of marihuana smoking in normal volunteers
US5549906A (en) Nicotine lozenge and therapeutic method for smoking cessation
Moncada et al. Prostacyclin is a circulating hormone
Domino Neuropsychopharmacologic studies of marijuana: Some synthetic and natural THC derivatives in animals and man
US20030084912A1 (en) Composition to reduce or quit smoking addiction
Travell Absorption of nicotine from various sites
US5760049A (en) Method for controlling tobacco use and alleviating withdrawal symptoms due to cessation of tobacco use
Silverman et al. Smoking characteristics of patients with oral carcinoma and the risk for second oral primary carcinoma
Herxheimer Atropine cigarettes in asthma and emphysema
US5512306A (en) Smoking substitute
US4655231A (en) Snuff and preparation thereof
US2892753A (en) Central nervous system stimulant
WO1996000072A1 (en) Treatment of nicotine craving and/or smoking withdrawal symptoms with a transdermal or transmucosal composition containing nicotine and caffeine or xanthine
US6045825A (en) Plantago major and Piper methysticum compound for use in treating a tobacco or nicotine habit
GB1315626A (en) Substituted p-menthanes and compositions containing them